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Abstract
The objectives of the present study were to assess the in vitro-induced
anti-hepatitis C virus (HCV) antibody production (IVIAP) in relation
to the clinical, biochemical, virologic and histologic variables of
patients with HCV infection. The study included 57 patients (60%
males) with HCV infection (anti-HCV and HCV-RNA positive).
Alanine aminotransferase (ALT) was elevated in 89% of the patients.
Mean viral load was 542,241 copies/ml and histology of the liver
showed chronic hepatitis in 27/52 (52%) and cirrhosis in 11/52 (21%)
patients. IVIAP levels were determined by immunoenzymatic assay at
median absorbance of 0.781 at 450 nm. IVIAP was negative in 14% of
the patients. When groups with IVIAP levels above and below the
median were compared, high IVIAP levels were associated with the
male sex, elevated ALT levels and more advanced disease stage. After
logistic regression analysis, advanced histologic damage to the liver
remained as the only independent variable associated with elevated
IVIAP levels. Using a receiver operator characteristic curve, the best
cut-off level for IVIAP was established (= 1.540), with 71% sensitiv-
ity and 94% specificity for the detection of more advanced disease
stages (grades 3 and 4). These findings are consistent with the partici-
pation of immunological mechanisms in the genesis of the hepatic
lesions induced by HCV and indicate that the IVIAP test may be useful
as a noninvasive marker of liver damage either alone or in combination
with other markers.
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Introduction
Infection with hepatitis C virus (HCV) is
widely distributed, with an estimated num-
ber of 170 million chronically infected indi-
viduals worldwide (1). The diagnostic ap-
proach to chronically HCV-infected patients
includes serologic and molecular biology tests
and especially histologic hepatic evaluation,
which permit an adequate characterization
of viral infection and of its repercussions on
the liver parenchyma.
However, many of these tests are expen-
sive or involve some risks to certain patients,
so that they cannot always be performed or
repeated several times. For this reason, diag-
nostic alternatives have been investigated
both in order to characterize patients with
active infection and to evaluate the extent of
histologic alteration of the liver in a noninva-
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sive manner.
It has been demonstrated for several viral
diseases that viral replication is related to in
vitro antibody secretion (2,3). Based on this
phenomenon, in 1994 Ducos et al. (4) de-
scribed a diagnostic test for hepatitis C which
was based on the relation between activation
of the immune system by viral antigens and
specific in vitro antibody secretion by pe-
ripheral blood lymphocytes. The objective
of the method was to differentiate between
carriers of active infection with viremia and
subjects with previous infection in the pres-
ence of an anti-HCV-positive test. In this
test, spontaneous in vitro antibody produc-
tion was observed after 8 days of incubation
in culture. When in vitro antibody produc-
tion results were compared to HCV-RNA
results, 100% agreement was found, sug-
gesting that active secretion of anti-HCV
antibodies by lymphocytes was related to
viral replication.
Variations of this method have been tested
for the diagnosis of other viral infections
such as cytomegalovirus (5,6) and HIV (3),
with a good correlation demonstrable be-
tween spontaneous antibody secretion and
viremia. On the basis of these findings,
Caterino-de-Araujo et al. (7) developed a
new laboratory method based on in vitro
antibody production, this time induced by
specific HIV antigens (in vitro-induced anti-
body production, IVIAP), which permitted
obtaining more rapid results at the end of 24
h of observation. The cited study showed
that the results of the test agreed with those
of HIV-RNA, with 91% sensitivity and 96%
specificity, in addition to the fact that the test
was rapid, practical and of low cost.
The use of IVIAP in hepatitis C was
evaluated only in patients under treatment
with interferon in a study which demon-
strated that a favorable response to treatment
was related to the reduction of antibody
production in vitro (Arrais TC and Granato
CF, unpublished results). However, there
are no studies in the literature in which IVIAP
behavior was studied in relation to epide-
miologic or virologic variables or to differ-
ent histologic stages of the disease in pa-
tients with chronic hepatitis C infection.
The objectives of the present study were
to assess the efficacy of the IVIAP test in
patients with chronic HCV infection not sub-
mitted to treatment, by analyzing the results
of IVIAP during the different phases of the
disease and its relation to different aspects of
HCV infection.
Patients and Methods
Patients
The study was conducted from October
1999 to February 2001 at the Hepatitis Out-
patient Clinic of the Gastroenterology Divi-
sion, Universidade Federal de São Paulo, on
selected patients with chronic hepatitis C
characterized by the presence of anti-HCV
antibodies (IMX®, Abbott Laboratories, Chi-
cago, IL, USA) and HCV-RNA positivity
(Amplicor® 2.1.1, Roche Diagnostics Cor-
poration, Indianapolis, IN, USA), who had
been submitted to a liver biopsy.
After approval of the study by the local
Ethics Committee and informed consent from
the subjects, patients of both sexes ranging
in age from 18 to 70 years were included in
the study. Patients co-infected with HBV
and/or HIV, patients under current treatment
or previously treated for hepatitis C, patients
with chronic renal failure or patients con-
suming more than 40 g ethanol/day were
excluded.
The epidemiologic, biochemical, viro-
logic and histologic characteristics of the
disease were related to the levels of  IVIAP.
Laboratory methods
Biochemical evaluation. Alanine ami-
notransferase (ALT) and aspartate ami-
notransferase were determined by an auto-
mated kinetic method (Cobas Mira, Roche
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Diagnostics, Basel, Switzerland). HCV-RNA
levels were determined using Amplicor®
Monitor kits (Roche Diagnostics). The limit
of sensitivity of the method reported by the
manufacturer is 500 copies/ml.
In vitro-induced antibody production.
The IVIAP test was based on the preparation
of peripheral blood lymphocytes in culture
with incubation on microtiter plates sensi-
tized with the HCV antigen (Diasorin®,
Diasorin Inc., Stillwater, MN, USA), fol-
lowed by quantification of specific antibody
production in vitro. Lymphocytes were ob-
tained from peripheral blood collected into
heparinized tubes by separation on Ficoll
Hypaque® (Pharmacia, Uppsala, Sweden).
The lymphocyte suspension was diluted with
RPMI medium containing 10% fetal calf
serum, with the concentration adjusted to 3 x
106 cells/ml. Two hundred microliters of this
cell suspension was added to the orifices of
the microplates, sensitized with HCV anti-
gen (recombinants C22 and C33 and syn-
thetic NS4 and NS5) and incubated for 18-
24 h at 37ºC in the presence of 5% CO2. On
the following day, the plates were washed
with 0.05% Tween 20-PBS and 100 µl of the
conjugate (goat IgG anti-human IgG) was
pipetted into the orifices of the microplate.
After incubation for 1 h at 37ºC and washing
three times, the substrate for the color reac-
tion was added. The plates were read 30 min
later by spectrophotometry at 450 nm. A
positive and a negative control (known stan-
dard sera, provided by the Diasorin kit) were
used and the cut-off was determined in each
test battery. The cut-off was calculated for
each assay and corresponded to twice the
absorbance value for the negative control.
Samples whose readings were above this
cut-off value were considered to be positive.
For the study of the relation between IVIAP
levels and variables of interest the results of
the tests were divided into two groups: a)
IVIAP values above the median obtained for
the sample (“high” IVIAP), and b) IVIAP
values below the median (“low” IVIAP).
Histologic evaluation. A liver biopsy was
performed 6 months before or after IVIAP
determination. The fragments of liver tissue
obtained by percutaneous biopsy with a Tru-
Cut® needle were fixed in 10% formalin and
stained with hematoxylin-eosin, Masson tri-
chrome, and Prussian blue (Perls method)
and by impregnation of reticular fibers with
silver (Gomori method). All the slides of the
liver biopsy were analyzed by a single pa-
thologist who evaluated necroinflammatory
portal/periportal activity and staging using
the semiquantification criteria proposed by
Ludwig (8) and Desmet et al. (9) for the
classification of chronic hepatitis.
Statistical analysis
Data were analyzed statistically using the
SPSS program, version 10.0 for Windows.
The quantitative variables are reported as
mean, standard deviation and median and
the qualitative variables as absolute (N) and
relative (%) frequency. Categorical variables
were analyzed by the chi-square test or
Fisher’s exact test when indicated.
The presence of a possible correlation
between IVIAP levels and viral load was
determined by the Spearman correlation co-
efficient.
Variables showing P<0.25 significance
were submitted to logistic regression analy-
sis for the identification of variables inde-
pendently associated with elevated IVIAP
levels. The receiver operator characteristic
(ROC) curve was used to identify the best
IVIAP value for the detection of more ad-
vanced staging (E3). On the basis of this
value, we identified the best sensitivity and
specificity value for IVIAP for the diagnosis
of more advanced staging (E3).
The level of significance was set at P<0.05
for all analyses.
Results
A total of 127 anti-HCV RNA-positive
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Of these 57 patients, 34 (60%) were males
and 23 (40%) females, ranging in age from
18 to 70 years (mean ± SD: 49 ± 13 years).
Twenty-three patients (40%) had received
blood transfusion and 6 (11%) were intrave-
nous drug users. Twenty-nine of the 57 pa-
tients (51%) presented a parenteral risk fac-
tor for HCV acquisition (Table 1).
ALT levels were abnormal in 51 patients
(89%), with a mean concentration of 2.7 x
the upper normal limit (UNL). Mean viral
load was 542,241 copies/ml (Table 1) and
hepatic histology showed the presence of
minimal changes in 14/52 patients (27%),
chronic hepatitis in 27/52 (52%), and cirrho-
sis in 11/52 (21%). In five patients the frag-
ments were not adequate for histologic anal-
ysis.
IVIAP levels determined in peripheral
blood lymphocytes incubated on ELISA
plates sensitized with HCV antigen showed
a median absorbance of 0.781. IVIAP was
negative in 8 patients (14%), i.e., below the
cut-off established for the test (Table 1).
Analysis by the Spearman correlation
coefficient showed no correlation between
IVIAP levels and viral load (r = 0.08, P =
0.55).
Comparison of IVIAP levels above and
below the median with the epidemiologic,
biochemical, virologic and histologic vari-
ables demonstrated that elevated IVIAP lev-
els were significantly associated with male
sex, ALT levels above normal, and more
advanced disease stages (grades 3 and 4;
Table 2).
After logistic regression analysis, more
advanced staging remained as the only vari-
able independently associated with elevated
antibody production in vitro (Table 3). For
this variable, the best cut-off value for IVIAP
(= 1.540) was established by means of a
ROC curve (Figure 1), with 71% sensitivity
and 94% specificity for the test in the detec-
tion of more advanced disease stages. The
positive predictive value was 86% and the
negative predictive value was 86%.
patients referred to the Hepatitis Outpatient
Clinic of Universidade Federal de São Paulo
were evaluated from October 1999 to Febru-
ary 2001 and 57 of them were included in the
study on the basis of the inclusion and exclu-
sion criteria.
Table 2. Comparison of patients with high and low in vitro-
induced antibody production (IVIAP) (total N = 57).
High IVIAP Low IVIAP
(N = 29) (N = 28)
Male sex 21 (72) 13 (46)*
Age 49 years 15 (51) 17 (61)
Parenteral risk factor 15 (51) 14 (50)
Elevated ALT 29 (100) 22 (79)*
Elevated AST 23 (79) 19 (68)
Viral load 542,241 copies/ml 15 (52) 14 (50)
Staging 3 12/24 (50) 5/25 (20)*
Portal/periportal activity 3 9/25 (36) 6/27 (22)
High and low refer to the median ELISA absorbance value at
450 nm: 0.781. Percent values are given in parentheses. ALT,
AST = alanine and aspartate aminotransferase, respectively.
*P<0.05 compared to high IVIAP (chi-square test).
Table 1. Epidemiologic and laboratory characteristics of the
subjects (N = 57).
Sex (M/F) 34/23
Age (years) 49 ± 13
Parenteral risk factor (%) 29 (51%)
History of blood transfusion 23 (40%)
Intravenous drug use 6 (11%)
Elevated ALT (%) 51 (89%)
ALT (x UNL) 2.7 ± 2.4
AST (x UNL) 1.8 ± 1.1
HCV viral load
No. of patients with HCV-RNA
>2 x 106 copies/ml 15 (25%)
Mean (copies/ml) 542,241
IVIAP (median) 0.781
IVIAP
Positive (%) 49 (86%)
Negative (%) 8 (14%)
Data are reported as means ± SD. M = male; F = female; UNL
= upper normal limit; ALT = alanine aminotransferase; AST =
aspartate aminotransferase; HCV = hepatitis C virus; IVIAP =
in vitro-induced antibody production.
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Discussion
In patients infected with HCV, active
secretion of anti-HCV antibodies by periph-
eral blood lymphocytes reflects the interac-
tion of the immune system with HCV anti-
gens and seems to be related to HCV replica-
tion and to hepatic dysfunction (4).
Measurement of IVIAP reflects persist-
ent antigenic stimulation of the immune sys-
tem, possibly induced by viral replication.
The IVIAP test used in combination with
quantitative HCV-RNA determination may
eventually provide supplementary informa-
tion about disease activity and about re-
sponse to treatment, thus being a candidate
for use as a new auxiliary laboratory test for
the diagnosis and monitoring of HCV infec-
tion.
The objective of the present study was to
evaluate the relation between IVIAP and
epidemiologic, virologic and histologic vari-
ables and to consider the possible applicabil-
ity of the test as a noninvasive method for the
evaluation of HCV-induced hepatic dam-
age.
The IVIAP test was positive in 49 pa-
tients (86%) and negative in 8 (14%). Al-
though patients with absent viremia (HCV-
RNA negative) were not studied to deter-
mine the specificity of the test in detecting
viremia, we conclude that the sensitivity of
the method for the characterization of vire-
mia was 86%. In a study of HCV-infected
patients submitted to antiviral treatment,
Arrais and Granato (Arrais TC and Granato
CF, unpublished results) obtained 88.2%
sensitivity, a value quite similar to the one
detected in the present study. In a study of in
vitro antibody production in patients with
chronic C virus infection, Ducos et al. (4), in
1994, also observed a good correlation be-
tween the secretion of anti-HCV antibodies
and viremia, with 64% sensitivity and 100%
specificity.
For patients with active disease and a
negative IVIAP test (only 8 in the present
study), we may assume a low production of
induced antibodies that did not permit their
detection by the methodology employed. The
mean absorbance obtained for the IVIAP
levels of the 57 patients studied was 1.056,
with a median of 0.781 and a standard devia-
tion of ± 0.868. Arrais and Granato (Arrais
TC and Granato CF, unpublished results)
detected mean pretreatment IVIAP levels of
1.200, ranging from 0.780 to 1.610, and
therefore closely similar to those detected in
the present study.
In the present study we analyzed the as-
sociation between IVIAP levels and epide-
miologic, biochemical, virologic and histo-
logic variables. For this purpose, the 57 pa-
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Figure 1. Cut-off point, sensitiv-
ity and specificity of in vitro-
induced antibody production in
the detection of advanced
stages (3 and 4) established by
a receiver operator characteris-
tic curve.
Table 3. Logistic regression analysis.
Initial model
Variable P
Sex 0.046
ALT 0.010
Staging 0.027
Final model
P OR  95% CI
Staging <0.001 35.98 6.12-211.48
ALT = alanine aminotransferase; OR = odds ratio;
CI = confidence interval.
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tients were divided into two groups accord-
ing to IVIAP levels, i.e., levels above the
median, and levels below the median. The
initial bivariate analysis performed showed
a statistically significant association between
elevated IVIAP levels and the following vari-
ables: sex (P = 0.04), high ALT levels (P =
0.01), and more advanced staging (P = 0.03).
Although the occurrence of higher IVIAP
levels among males has not been established,
this finding in the present study appears to be
related to the worse disease course in male
patients, as demonstrated by others (10).
Indeed, when the logistic regression model
was used to evaluate the variables independ-
ently associated with more elevated IVIAP
levels, more advanced staging was the only
variable showing this association. The rea-
son why male patients develop hepatic fibro-
sis more rapidly and more advanced staging
grades is not clear, but appears to be related
to other factors such as greater alcohol con-
sumption (10,11), more common among men,
or to greater iron accumulation in the liver,
which appear to determine a worse histologic
evolution among HCV-infected patients (12).
No significant association was observed
between IVIAP levels and age or transmis-
sion risk factors.
Comparative analysis concerning the bio-
chemical characteristics showed that elevated
IVIAP levels were significantly associated
with elevated ALT levels (above 1 x UNL)
(P = 0.01). This suggests that hepatic dam-
age must be related to the immune system
which may act not only on the virus, but also
on the hepatic parenchyma, causing hepato-
cellular damage and also being responsible
for the pathogenesis of chronic HCV infec-
tion. In a study of in vitro antibody produc-
tion in HCV infection, Ducos et al. (4) also
detected a statistically significant associa-
tion between a positive test and elevated
ALT levels (P<0.001). Similarly, Arrais and
Granato also demonstrated similar ALT
curves and IVIAP levels during the treat-
ment of hepatitis, i.e., a decrease in ALT
levels with decreasing IVIAP levels at 30, 60
and 90 days of treatment (Arrais TC and
Granato CF, unpublished results).
After logistic regression analysis, ALT
was not independently associated with el-
evated IVIAP levels, showing that its corre-
lation was probably mediated by structural
hepatic damage for which ALT was possibly
acting as an indirect marker.
Also, no significant correlation was ob-
served between viral load and IVIAP levels
(P = 0.37). The correlation between the pres-
ence of viremia and in vitro antibody pro-
duction seems to be clear, as also demon-
strated in other studies (4,13). However, the
levels of viral load were not studied in any of
these investigations and the dynamic rela-
tionship between antibody production and
viral clearance is still unknown. The rela-
tionship between these variables (viral load
and antibody levels) may be modulated by
mechanisms used by HCV to avoid the hu-
moral and cellular immune response as the
disease progresses to chronic hepatitis. It is
possible that the immune response is qualita-
tively and quantitatively insufficient to de-
stroy all infected cells (14), causing a lack of
relation between antibody levels and viral
load in chronically infected patients.
With respect to the histologic variables, a
statistically significant and independent as-
sociation was observed between elevated
IVIAP levels and more advanced staging
(P = 0.03). Although the mechanisms that
cause increased production of anti-HCV anti-
bodies are not clear, this finding suggests the
participation of immune-mediated mechan-
isms in the pathogenesis of the disease (4),
causing a more significant fibrosis progres-
sion in patients with higher antibody levels.
The higher antibody levels observed could
be an epiphenomenon of the immune re-
sponse elicited mainly by the cellular com-
ponent and may not have a direct pathogenic
role.
With respect to portal/periportal activity,
there was no significant difference between
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this histologic variable and high IVIAP lev-
els (P = 0.55). Similarly, when analyzing
pretreatment hepatic biopsies, Arrais and
Granato (Arrais TC and Granato CF, unpub-
lished results) also did not find a significant
association between elevated IVIAP levels
and portal/periportal activity in 20 patients
studied (P = 0.6). They also obtained a sig-
nificant relationship with staging, as was the
case for the present study (P = 0.04), show-
ing that antibody production is somehow
associated with an increased rate of fibrosis
progression.
Since staging was the only variable that
showed independent association with high
IVIAP levels, a ROC curve was calculated to
determine the cut-off point for IVIAP with
the highest sensitivity and specificity for the
detection of more advanced staging. With a
cut-off point for IVIAP of 1.540, sensitivity
was 71% and specificity 94%, showing that
IVIAP, with this proposed cut-off level, could
function as an indirect and noninvasive test
for patients who cannot be submitted to a
liver biopsy.
The search for noninvasive tests for the
evaluation of hepatic damage induced by
HCV has been a constant concern in clinical
practice since the patients cannot always be
submitted to a liver biopsy due to contraindi-
cations, especially coagulation disorders that
prevent the procedure. In addition, multiple
biopsies are often necessary during follow-
up, increasing patient discomfort and risk.
Thus, several tests have been proposed in
an attempt to indirectly evaluate the degrees
of derangement of the underlying hepatic
structural architecture. Tests such as deter-
mination of serum laminin (15), type III
procollagen (16), gamma-glutamyltrans-
ferase (17,18) and hyaluronic acid (19),
among others, have been proposed with this
objective, providing sensitivity rates ranging
from 34 to 76% and specificity from 71 to
100%. More recently, the combination of
several of these tests has been proposed (20),
with a considerable increase in predictive
value. Thus, the IVIAP test may contribute
to the noninvasive evaluation of histologic
hepatic damage, especially of the degree of
underlying hepatic fibrosis either separately
or in combination with other noninvasive
tests, since it showed good positive and nega-
tive predictive values.
The IVIAP test, which was used to evalu-
ate the in vitro production of anti-HCV anti-
bodies in patients with chronic HCV infec-
tion, showed an association between elevated
antibody levels and male sex, elevated ALT
level, and more advanced grades of histo-
logic staging. Staging was the only variable
showing independent association with high
IVIAP levels upon logistic regression analy-
sis. These findings suggest the participation
of immunologic mechanisms in the genesis
of the hepatic lesions induced by HCV, al-
though a direct pathogenic role of antibodies
cannot be proposed on the basis of the pres-
ent study. Our findings also indicate that the
IVIAP test may be useful as a noninvasive
marker of histologic hepatic damage either
alone or in combination with other markers.
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